Literature DB >> 24469272

Drug-free holiday in patients with rheumatoid arthritis: a qualitative study to explore patients' opinion.

I M Markusse1, G Akdemir, T W J Huizinga, C F Allaart.   

Abstract

Clinical trials have shown that in patients with long-standing low disease activity, tapering and/or stopping antirheumatic medication is a realistic option. The objective of this study is to explore patients' opinion about tapering and discontinuing antirheumatic drugs. This qualitative study is based on interviews with 20 patients with rheumatoid arthritis (RA) about RA treatment and treatment discontinuation through structured interviewing. Interviews were tape-recorded, transcribed verbatim, and screened by three assessors independently for meaning units. Not only positive emotions about drug discontinuation such as hope, happiness, and relief, but also fear and disappointment were mentioned. Some patients expect that drug discontinuation will be possible in other patients and/or themselves, while others do not expect this. The concept of increase in disease activity after discontinuing medication was mentioned, and while patients expect that disease activity will decrease again after restarting medication, they expect that this will take (too much) time. Positive emotions about the option to taper and discontinue antirheumatic medication, with negative expectations is a common combination in these RA patients. In particular, patients expect that disease activity will flare and that improvement upon restarting medication will take time. Patients' expectations and feelings should be addressed before drug tapering is attempted in a clear strategy of continued monitoring of disease activity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24469272     DOI: 10.1007/s10067-014-2500-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

1.  The role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review.

Authors:  R Crow; H Gage; S Hampson; J Hart; A Kimber; H Thomas
Journal:  Health Technol Assess       Date:  1999       Impact factor: 4.014

2.  Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.

Authors:  Jacqueline Detert; Hans Bastian; Joachim Listing; Anja Weiß; Siegfried Wassenberg; Anke Liebhaber; Karin Rockwitz; Rieke Alten; Klaus Krüger; Rolf Rau; Christina Simon; Eva Gremmelsbacher; Tanja Braun; Bettina Marsmann; Vera Höhne-Zimmer; Karl Egerer; Frank Buttgereit; Gerd-R Burmester
Journal:  Ann Rheum Dis       Date:  2012-06-27       Impact factor: 19.103

3.  Validating the International Classification of Functioning, Disability and Health Comprehensive Core Set for Rheumatoid Arthritis from the patient perspective: a qualitative study.

Authors:  Tanja A Stamm; Alarcos Cieza; Michaela Coenen; Klaus P Machold; Valerie P K Nell; Josef S Smolen; Gerold Stucki
Journal:  Arthritis Rheum       Date:  2005-06-15

4.  What is an adequate sample size? Operationalising data saturation for theory-based interview studies.

Authors:  Jill J Francis; Marie Johnston; Clare Robertson; Liz Glidewell; Vikki Entwistle; Martin P Eccles; Jeremy M Grimshaw
Journal:  Psychol Health       Date:  2010-12

5.  Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study.

Authors:  N B Klarenbeek; S M van der Kooij; M Güler-Yüksel; J H L M van Groenendael; K H Han; P J S M Kerstens; T W J Huizinga; B A C Dijkmans; C F Allaart
Journal:  Ann Rheum Dis       Date:  2010-11-10       Impact factor: 19.103

6.  What factors account for referral delays for patients with suspected rheumatoid arthritis?

Authors:  Lisa G Suter; Liana Fraenkel; Eric S Holmboe
Journal:  Arthritis Rheum       Date:  2006-04-15

7.  Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.

Authors:  S M van der Kooij; Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; M Güler-Yüksel; A H Zwinderman; P J S M Kerstens; P A H M van der Lubbe; W M de Beus; B A M Grillet; H K Ronday; T W J Huizinga; F C Breedveld; B A C Dijkmans; C F Allaart
Journal:  Ann Rheum Dis       Date:  2008-07-28       Impact factor: 19.103

8.  Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission.

Authors:  Masao Nawata; Kazuyoshi Saito; Shingo Nakayamada; Yoshiya Tanaka
Journal:  Mod Rheumatol       Date:  2008-06-06       Impact factor: 3.023

9.  Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2007-07

10.  Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis.

Authors:  S ten Wolde; F C Breedveld; J Hermans; J P Vandenbroucke; M A van de Laar; H M Markusse; M Janssen; H R van den Brink; B A Dijkmans
Journal:  Lancet       Date:  1996-02-10       Impact factor: 79.321

View more
  5 in total

1.  What Are the Preferences of Patients With Rheumatoid Arthritis for Treatment Modification? A Scoping Review.

Authors:  Suz Jack Chan; Hui Yee Yeo; Lisa K Stamp; Gareth J Treharne; Carlo A Marra
Journal:  Patient       Date:  2020-12-18       Impact factor: 3.883

Review 2.  bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search.

Authors:  Lise M Verhoef; Lieke Tweehuysen; Marlies E Hulscher; Bruno Fautrel; Alfons A den Broeder
Journal:  Rheumatol Ther       Date:  2017-03-02

3.  "Living a normal life": a qualitative study of patients' views of medication withdrawal in rheumatoid arthritis.

Authors:  Kenneth F Baker; John D Isaacs; Ben Thompson
Journal:  BMC Rheumatol       Date:  2019-06-13

4.  Making Decisions About Stopping Medicines for Well-Controlled Juvenile Idiopathic Arthritis: A Mixed-Methods Study of Patients and Caregivers.

Authors:  Daniel B Horton; Jomaira Salas; Aleksandra Wec; Melanie Kohlheim; Pooja Kapadia; Timothy Beukelman; Alexis Boneparth; Ky Haverkamp; Melissa L Mannion; L Nandini Moorthy; Sarah Ringold; Marsha Rosenthal
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-03       Impact factor: 4.794

5.  Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.

Authors:  Benjamin Birkner; Jürgen Rech; Tom Stargardt
Journal:  PLoS One       Date:  2020-01-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.